Tango Therapeutics, Inc. (TNGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 4, 2026, details the results of the 2026 Annual Meeting of Stockholders held virtually on that date. The meeting addressed the election of directors, ratification of the independent auditor, and an advisory vote on executive compensation.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Shareholder Participation: As of the record date (April 7, 2026), 144,242,271 shares were outstanding. 131,198,081 shares (90.96%) were present or represented by proxy, establishing a quorum.
Proposal 1: Election of Class II Directors
- Malte Peters, M.D. was elected with 98,188,796 votes "For" and 17,623,596 "Withheld".
- Mace Rothenberg, M.D. was elected with 92,476,172 votes "For" and 23,336,220 "Withheld".
- Board Change: Kanishka Pothula resigned as a director effective May 13, 2026, and did not stand for re-election. His resignation was not due to any disagreement with the Company.
Proposal 2: Ratification of Independent Auditor
- PricewaterhouseCoopers, LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes: 131,097,992 "For", 73,823 "Against", 26,266 "Abstain".
Proposal 3: Executive Compensation Advisory Vote
- Stockholders approved the non-binding advisory vote on named executive officer compensation.
- Votes: 113,915,877 "For", 1,855,838 "Against", 40,677 "Abstain".
Guidance, Outlook, and Risks
The filing text does not contain management guidance, financial outlook, risk factors, or contingencies. It is a procedural report of shareholder voting results.
Key Facts for Investor Verification
- Verify the final composition of the Board of Directors following the election of Dr. Peters and Dr. Rothenberg and the resignation of Mr. Pothula.
- Confirm the appointment of PricewaterhouseCoopers, LLP for the 2026 fiscal year audit.
- Review the Proxy Statement filed on April 17, 2026, for detailed biographies of the elected directors and the specific compensation metrics approved in Proposal 3.
- Note that the filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.